Potential role of immunotherapy in advanced non-small-cell lung cancer

• Autor(a) principal: De Mello, Ramon Andrade
• Data de Publicação: 2017
• Outros Autores: Veloso, Ana Flavia, Catarina, Paulo Esrom, Nadine, Sara, Antoniou, Georgios
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.1/12006
• topic: Immune checkpoint inhibitors; Predictive biomarker; Tumor escape; Ifn-gamma; Nivolumab; Immunosurveillance; Anti-Pd-1; Nsclc; Suppression; Management

Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) or with anaplastic lymphoma kinase inhibitors (eg, crizotinib and ceritinib). As a result, anti-PD- 1/PD-L1 and CTLA-4 inhibitors may play a novel role in the improvement of outcomes in a metastatic setting. The regulation of immune surveillance, immunoediting, and immunoescape mechanisms may play an interesting role in this regard either alone or in combination with current drugs. Here, we discuss advances in immunotherapy for the treatment of metastatic non-small-cell lung cancer as well as future perspectives within this framework.